#USA #Fort Lauderdale #Wound Care #MolecuLight #CAMPS 2025

MolecuLight Showcases Innovative Imaging Technology at CAMPS 2025

MolecuLight Inc. is thrilled to announce its participation in the 2025 Cellular, Acellular, and Matrix-like Products (CAMPS) Wound Care Summit, taking place from February 28 to March 2 in Fort Lauderdale, Florida. This event promises an exciting platform where attendees can explore cutting-edge advancements in wound care management.

As a front-runner in Point-of-Care fluorescence imaging devices for wound care, MolecuLight will demonstrate how its innovative technology can significantly improve wound assessment, measurement, documentation, and treatment decisions concerning CAMPS. Notably, this conference session will provide insights related to the proposed new language for local coverage determination (LCD) for skin grafts and substitutes.

Real-Time Insights for Better Patient Outcomes

The fluorescence imaging technology offered by MolecuLight enables clinicians to instantly visualize harmful bacterial loads in wounds associated with infections and the failure of CAMPS. This real-time visibility arms healthcare professionals with the necessary information to treat patients more effectively, leading to faster wound closure and improved clinical outcomes. The MolecuLight devices guide targeted therapies, such as preparing the wound bed for CAMPS, and optimize treatment strategies based on immediate, actionable data.

Anil Amlani, CEO of MolecuLight, remarked, "Our technology addresses a critical gap in wound care by allowing clinicians to see what they would not otherwise detect. By illuminating the presence of bacteria, we can support the efficacy of novel therapies like CAMPS, leading to better patient outcomes and ultimately reducing the burden of chronic wounds."

The proposed new LCD language for skin substitutes emphasizes the importance of thorough wound assessment and documentation. MolecuLight's comprehensive wound imaging and measurement devices dovetail with these needs by providing:

• - Objective, visual evidence of wound conditions
• - Automated, precise wound measurements
• - Enhanced documentation to justify the medical necessity of advanced therapies

Amlani further explained, "MolecuLight’s ability to provide real-time objective data aligns perfectly with evolving standards for wound documentation and treatment. We are eager to showcase how our technology can help healthcare providers meet the requirements of the proposed LCD language while ensuring optimal patient care."

Visit MolecuLight at CAMPS 2025

Attendees of the CAMPS Meeting 2025 are invited to visit MolecuLight at booth #21 to experience the technology firsthand and learn about its applications not only in CAMPs but across the spectrum of wound care. Participants are also encouraged to attend the breakout session entitled "How to Ensure Optimal Outcomes with CAMPS" on February 28 from 11:25 AM to 12:45 PM, where MolecuLight will discuss its innovative technology aimed at enhancing wound bed preparation for optimized CAMP outcomes.

About MolecuLight

MolecuLight Inc. is a privately held medical imaging company with a global footprint, known for manufacturing and distributing the MolecuLight iX® and DX™ wound imaging devices. These are the only FDA-approved Point-of-Care imaging devices of Class II that offer real-time detection of elevated bacterial loads in wounds. Additionally, they provide accurate digital wound measurements, supporting comprehensive wound management grounded in solid clinical evidence, including over 100 peer-reviewed publications.

For sales inquiries, media requests, or further information, please contact Hunter Zudans, Marketing Manager, at MolecuLight Inc. T. +1.484.682.7580 [email protected] www.moleculight.com